BALPHARMA vs DCAL: Stock Comparison
DISHMAN CARBO AMCIS is the larger company by market capitalisation. BALPHARMA shows a higher ROE, a higher dividend yield and a higher ROCE, while DISHMAN CARBO AMCIS shows faster revenue growth, lower leverage and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BALPHARMA leads 5; DCAL leads 4 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BALPHARMA | DCAL |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | BALPHARMA | DCAL |
|---|---|---|
| Live Price | ₹106.79 | ₹140.02 |
| Day Change | 0.99% | -1.46% |
| Volume | 25,522 | 1.95 L |
| 52-Week High | ₹124.6 | ₹303 |
| 52-Week Low | ₹60 | ₹128.5 |
| Distance from 52W High | -14.29% | -53.79% |
Valuation
| Metric | BALPHARMA | DCAL |
|---|---|---|
| Market Cap | ₹134 Cr | ₹2,195 Cr |
| P/E Ratio | — | 135.92x |
| P/B Ratio | — | 0.33x |
| EPS | ₹0.71 | ₹-3.69 |
| Book Value | ₹51.66 | ₹425.87 |
| Dividend Yield | 1.36% | 0% |
Growth
| Metric | BALPHARMA | DCAL |
|---|---|---|
| Revenue Growth (TTM YoY) | 2.7% | 18.9% |
| EPS Growth (TTM YoY) | -33.5% | -49.5% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | BALPHARMA | DCAL |
|---|---|---|
| ROE | 6.49% | -0.99% |
| ROCE | 9.07% | 0.61% |
| Net Margin | 2.02% | 2.51% |
| Operating Margin | 7.46% | 11.78% |
| Debt to Equity | 1.48x | 0.16x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | BALPHARMA | DCAL |
|---|---|---|
| Promoter Holding | 46.74% | 59.32% |
| FII Holding | 0.28%▲ 0.13 pp | 6.86%▼ 0.59 pp |
| DII Holding | 0% | 2.07%▲ 0.44 pp |
| Public Holding | 48.87%▼ 0.12 pp | 31.75%▲ 0.15 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BALPHARMA and DISHMAN CARBO AMCIS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.